| 2016 |
Julia Vogel |
Assent - differences in Europe and potential for harmonization |
|
|
| 2016 |
Cornelia Wagner |
Overview of the Active Substance Master File Approaches in the European Union, Japan, Brazil, Russia and the World Health Organization from the Perspective of an API Manufacturer of Small Molecules |
|
|
| 2016 |
Svetlana Walter |
Dependencies between marketing authorisations in Developed and Emerging Markets – Implications for Regulatory Strategy *** |
|
|
| 2016 |
Immanuel Weber |
New safety features against falsified medicines according to the Delegated Regulation (EU) 2016/161: Consequences for Parallel Distributors |
|
|
| 2016 |
Dr. Ruth Zeller-Adam |
The European Council's Partial General Approach to the Proposal for a Medical Device Regulation: Its potential implications on demarcation, classification, and conformity assessment of substance-based medical devices *** |
|
|
| 2016 |
Dr. Valeria Ziemann |
Overview of Regulatory Requirements for Marketing Authorisations of Pharmaceutical Products in Countries of Eurasian Economic Union |
|
|
| 2016 |
Astrid Zimmermann |
Regulatory Requirements of Marketing Authorization Holder Transfers in International Markets |
|
|
| 2016 |
Dr. Ina Zschocke |
Standard for Outcome Measures in Clinical Trials for the treatment of plaque psoriasis supporting Labelling Claim and their application in practice – a critical review of the EMA Guideline CHMP/EWP/2454/02corr and a proposal for future development *** |
|
|
| 2015 |
Dr. Andrea Abele |
Skinny labelling *** |
|
|
| 2015 |
Pablo Gabriel Amaya Rodriguez |
Pharmaceutical pricing and reimbursement in Latin America - Implications for Regulatory Strategy *** |
|
|
| 2015 |
Dr. Jennifer Anthöfer |
Drug Development and Critical Analysis of the Reliability of Preclinical Studies *** |
|
|
| 2015 |
Dr. Kerstin Bade |
The revision of European Directives on medical devices 90/385/EWG (AIMDD) and 93/42/EWG (MDD): Present requirements concerning clinical investigation and clinical evaluation in comparison to Commission`s proposal for a new Regulation on medical devices and those discussed by the EU Parliament and the Council in the course of the legislation procedure |
|
|
| 2015 |
Cora Bergmann |
Sunset Clause in Germany – Provisions for nationally authorised human medicinal products under the responsibility of the Federal Institut for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) |
|
|
| 2015 |
Bettina Bickel |
Heparin - Changes in regulatory requirements and consequences thereof *** |
|
|
| 2015 |
Olga Borsuk |
The repurposing of already marketing drugs to be used in the field of rare diseases: challenges, advantages and regulatory strategy in the European Union |
|
|
| 2015 |
Yuan Chen |
Article 58 Applications - Best Access to Drugs in Developing Countries? *** |
|
|
| 2015 |
Simone Dietz |
Implementation of GDP (2013/C 343/01) - from a logistic supplier's point of view *** |
|
|
| 2015 |
Dr. Florian Diwischek |
Regulatory Approval options in emergency situations - a comparison between EU and US on the example of the Ebola virus *** |
|
|
| 2015 |
Dr. Alina Frantescu |
National dossier requirements in the European countries – Last step in obtaining the marketing authorisation or rather a burden for the applicant? *** |
|
|
| 2015 |
Sabine Günther-Commerscheidt |
Status quo 2015 - Post-Authorisation Pharmacovigilance for Human and Veterinary Medicinal Products in Germany and Europe |
|
|
